Product Description
Poloxamers, also known as Pluronics®, are block copolymers of poly(ethylene oxide) (PEO) and poly(propylene oxide) (PPO), which have an amphiphilic character and useful association and adsorption properties emanating from this. (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5872097/)
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical,Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Australia | Colombia | Germany | Ireland | Italy | New Zealand | Pakistan | Russia | Taiwan | Thailand | United Arab Emirates
Approved Indications: None
Known Adverse Events: None
Company: Savara
Company Location: AUSTIN TX 78746
Company CEO: Matthew Pauls
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Genital Diseases, Female|Anemia, Sickle Cell
Phase 2: Keratitis|Herpes Zoster|Burns Unspecified|Eye Burns|Corneal Transplant
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| antiadhesion | P3 |
Unknown status |
Genital Diseases, Female |
2017-07-01 |
|
| NTX-PED-001 | P2 |
Terminated |
Corneal Transplant|Burns Unspecified|Eye Burns|Keratitis|Herpes Zoster |
2014-02-01 |
|
| CYTRX-C97-1248 | P3 |
Completed |
Anemia, Sickle Cell |
None |